The hallmarks of successful anticancer immunotherapy

被引:447
作者
Galluzzi, Lorenzo [1 ,2 ,3 ]
Chan, Timothy A. [4 ,5 ,6 ]
Kroemer, Guido [3 ,7 ,8 ,9 ,10 ,11 ,12 ]
Wolchok, Jedd D. [6 ,13 ,14 ]
Lopez-Soto, Alejandro [15 ]
机构
[1] Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY 10065 USA
[2] Sandra & Edward Meyer Canc Ctr, New York, NY 10065 USA
[3] Univ Paris Descartes Paris V, F-75006 Paris, France
[4] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA
[5] Mem Sloan Kettering Canc Ctr, Immunogen & Precis Oncol Platform, New York, NY 10065 USA
[6] Weill Cornell Sch Med, New York, NY 10065 USA
[7] Ctr Rech Cordeliers, Equipe Labellisee Ligue Natl Canc 11, F-75006 Paris, France
[8] INSERM, U1138, F-75006 Paris, France
[9] Univ Pierre & Marie Curie Paris VI, F-75006 Paris, France
[10] Gustave Roussy Comprehens Canc Ctr, Metabol & Cell Biol Platforms, F-94805 Villejuif, France
[11] Hop Europeen Georges Pompidou, AP HP, Pole Biol, F-75015 Paris, France
[12] Karolinska Univ Hosp, Dept Womens & Childrens Hlth, S-17176 Stockholm, Sweden
[13] Mem Sloan Kettering Canc Ctr, Parker Inst, Dept Med, New York, NY 10065 USA
[14] Mem Sloan Kettering Canc Ctr, Ludwig Ctr, New York, NY 10065 USA
[15] Univ Oviedo, IUOPA, Inst Invest Sanitaria Principado Asturias ISPA, Dept Biol Func,Area Inmunol, Oviedo 33006, Spain
基金
欧洲研究理事会;
关键词
IMMUNE-CHECKPOINT BLOCKADE; NATURAL-KILLER-CELLS; PD-1; BLOCKADE; IFN-GAMMA; NK CELLS; TUMOR MICROENVIRONMENT; ACQUIRED-RESISTANCE; CANCER RESPONSE; CTLA-4; PLASMA-CELLS;
D O I
10.1126/scitranslmed.aat7807
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Immunotherapy is revolutionizing the clinical management of multiple tumors. However, only a fraction of patients with cancer responds to immunotherapy, and currently available immunotherapeutic agents are expensive and generally associated with considerable toxicity, calling for the identification of robust predictive biomarkers. The overall genomic configuration of malignant cells, potentially favoring the emergence of immunogenic tumor neoantigens, as well as specific mutations that compromise the ability of the immune system to recognize or eradicate the disease have been associated with differential sensitivity to immunotherapy in preclinical and clinical settings. Along similar lines, the type, density, localization, and functional orientation of the immune infiltrate have a prominent impact on anticancer immunity, as do features of the tumor microenvironment linked to the vasculature and stroma, and systemic factors including the composition of the gut microbiota. On the basis of these considerations, we outline the hallmarks of successful anticancer immunotherapy.
引用
收藏
页数:14
相关论文
共 157 条
[1]   Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution [J].
Abbosh, Christopher ;
Birkbak, Nicolai J. ;
Wilson, Gareth A. ;
Jamal-Hanjani, Mariam ;
Constantin, Tudor ;
Salari, Raheleh ;
Le Quesne, John ;
Moore, David A. ;
Veeriah, Selvaraju ;
Rosenthal, Rachel ;
Marafioti, Teresa ;
Kirkizlar, Eser ;
Watkins, Thomas B. K. ;
McGranahan, Nicholas ;
Ward, Sophia ;
Martinson, Luke ;
Riley, Joan ;
Fraioli, Francesco ;
Al Bakir, Maise ;
Gronroos, Eva ;
Zambrana, Francisco ;
Endozo, Raymondo ;
Bi, Wenya Linda ;
Fennessy, Fiona M. ;
Sponer, Nicole ;
Johnson, Diana ;
Laycock, Joanne ;
Shafi, Seema ;
Czyzewska-Khan, Justyna ;
Rowan, Andrew ;
Chambers, Tim ;
Matthews, Nik ;
Turajlic, Samra ;
Hiley, Crispin ;
Lee, Siow Ming ;
Forster, Martin D. ;
Ahmad, Tanya ;
Falzon, Mary ;
Borg, Elaine ;
Lawrence, David ;
Hayward, Martin ;
Kolvekar, Shyam ;
Panagiotopoulos, Nikolaos ;
Janes, Sam M. ;
Thakrar, Ricky ;
Ahmed, Asia ;
Blackhall, Fiona ;
Summers, Yvonne ;
Hafez, Dina ;
Naik, Ashwini .
NATURE, 2017, 545 (7655) :446-+
[2]   High-Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue Specialization [J].
Alcantara-Hernandez, Marcela ;
Leylek, Rebecca ;
Wagar, Lisa E. ;
Engleman, Edgar G. ;
Keler, Tibor ;
Marinkovich, M. Peter ;
Davis, Mark M. ;
Nolan, Garry P. ;
Idoyaga, Juliana .
IMMUNITY, 2017, 47 (06) :1037-+
[3]   The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets [J].
Allard, Bertrand ;
Longhi, Maria Serena ;
Robson, Simon C. ;
Stagg, John .
IMMUNOLOGICAL REVIEWS, 2017, 276 (01) :121-144
[4]  
Andrews Audrey, 2015, Am Health Drug Benefits, V8, P9
[5]   PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Lesokhin, Alexander M. ;
Borrello, Ivan ;
Halwani, Ahmad ;
Scott, Emma C. ;
Gutierrez, Martin ;
Schuster, Stephen J. ;
Millenson, Michael M. ;
Cattry, Deepika ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Chapuy, Bjoern ;
Ligon, Azra H. ;
Zhu, Lili ;
Grosso, Joseph F. ;
Kim, Su Young ;
Timmerman, John M. ;
Shipp, Margaret A. ;
Armand, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319
[6]   Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia [J].
Baginska, Joanna ;
Viry, Elodie ;
Berchem, Guy ;
Poli, Aurelie ;
Noman, Muhammad Zaeem ;
van Moer, Kris ;
Medves, Sandrine ;
Zimmer, Jacques ;
Oudin, Anais ;
Niclou, Simone P. ;
Bleackley, R. Chris ;
Goping, Ing Swie ;
Chouaib, Salem ;
Janji, Bassam .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (43) :17450-17455
[7]   Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies [J].
Bahrami, Afsane ;
Khazaei, Majid ;
Bagherieh, Fariba ;
Ghayour-Mobarhan, Majid ;
Maftouh, Mina ;
Hassanian, Seyed Mahdi ;
Avan, Amir .
JOURNAL OF CELLULAR PHYSIOLOGY, 2017, 232 (11) :2931-2937
[8]   Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer [J].
Balachandran, Vinod P. ;
Luksza, Marta ;
Zhao, Julia N. ;
Makarov, Vladimir ;
Moral, John Alec ;
Remark, Romain ;
Herbst, Brian ;
Askan, Gokce ;
Bhanot, Umesh ;
Senbabaoglu, Yasin ;
Wells, Daniel K. ;
Cary, Charles Ian Ormsby ;
Grbovic-Huezo, Olivera ;
Attiyeh, Marc ;
Medina, Benjamin ;
Zhang, Jennifer ;
Loo, Jennifer ;
Saglimbeni, Joseph ;
Abu-Akeel, Mohsen ;
Zappasodi, Roberta ;
Riaz, Nadeem ;
Smoragiewicz, Martin ;
Kelley, Z. Larkin ;
Basturk, Olca ;
Goenen, Mithat ;
Levine, Arnold J. ;
Allen, Peter J. ;
Fearon, Douglas T. ;
Merad, Miriam ;
Gnjatic, Sacha ;
Iacobuzio-Donahue, Christine A. ;
Wolchok, Jedd D. ;
DeMatteo, Ronald P. ;
Chan, Timothy A. ;
Greenbaum, Benjamin D. ;
Merghoub, Taha ;
Leach, Steven D. .
NATURE, 2017, 551 (7681) :512-+
[9]   Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].
Balar, Arjun V. ;
Galsky, Matthew D. ;
Rosenberg, Jonathan E. ;
Powles, Thomas ;
Petrylak, Daniel P. ;
Bellmunt, Joaquim ;
Loriot, Yohann ;
Necchi, Andrea ;
Hoffman-Censits, Jean ;
Perez-Gracia, Jose Luis ;
Dawson, Nancy A. ;
van der Heijden, Michiel S. ;
Dreicer, Robert ;
Srinivas, Sandy ;
Retz, Margitta M. ;
Joseph, Richard W. ;
Drakaki, Alexandra ;
Vaishampayan, Ulka N. ;
Sridhar, Srikala S. ;
Quinn, David I. ;
Duran, Ignacio ;
Shaffer, David R. ;
Eigl, Bernhard J. ;
Grivas, Petros D. ;
Yu, Evan Y. ;
Li, Shi ;
Kadel, Edward E., III ;
Boyd, Zachary ;
Bourgon, Richard ;
Hegde, Priti S. ;
Mariathasan, Sanjeev ;
Thastrom, AnnChristine ;
Abidoye, Oyewale O. ;
Fine, Gregg D. ;
Bajorin, Dean F. .
LANCET, 2017, 389 (10064) :67-76
[10]   The spectrum of T cell metabolism in health and disease [J].
Bantug, Glenn R. ;
Galluzzi, Lorenzo ;
Kroemer, Guido ;
Hess, Christoph .
NATURE REVIEWS IMMUNOLOGY, 2018, 18 (01) :19-34